

Montserrat Muoz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1327540/montserrat-munoz-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98 papers	3,672 citations	35 h-index	59 g-index
108 ext. papers	4,531 ext. citations	7 avg, IF	4.61 L-index

#	Paper	IF	Citations
98	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015 , 24 Suppl 2, S26-35.	3.6	450
97	Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4746-51	2.2	214
96	Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. <i>Cell Reports</i> , 2014 , 6, 514-27	10.6	194
95	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 545-554	21.7	175
94	Adjuvant docetaxel for high-risk, node-negative breast cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 2200-10	59.2	149
93	Gender, age, socio-demographic and lifestyle factors associated with major dietary patterns in the Spanish Project SUN (Seguimiento Universidad de Navarra). <i>European Journal of Clinical Nutrition</i> , 2003 , 57, 285-92	5.2	136
92	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 2213-2221	10.1	109
91	A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 811-6	12.9	104
90	Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1045-52	2.2	97
89	18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 1551-7	8.8	91
88	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. <i>Breast Cancer Research and Treatment</i> , 1998 , 51, 109-19	4.4	89
87	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , 2015 , 13, 303	11.4	87
86	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. <i>Breast Cancer Research</i> , 2005 , 7, 1	8.3	78
85	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER breast cancer. <i>Nature Cell Biology</i> , 2018 , 20, 211-221	23.4	71
84	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology, The</i> , 2011 , 12, 369-76	21.7	68
83	Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 60, 715-21	4	66
82	Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3636-3636	2.2	65

81	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. <i>JAMA Oncology</i> , 2016 , 2, 1287-1294	13.4	65
80	Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. <i>Clinical Chemistry</i> , 2010 , 56, 1148-57	5.5	58
79	Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. <i>British Journal of Cancer</i> , 1996 , 74, 1126-31	8.7	58
78	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 45	8.3	55
77	Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. <i>Tumor Biology</i> , 2010 , 31, 171-80	2.9	54
76	Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. <i>Journal of Pathology</i> , 1997 , 182, 160-6	9.4	54
75	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2020 , 21, 33-43	21.7	52
74	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 507-15	4.4	46
73	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018 , 67, 63-70	14.4	45
72	Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2593-9	2.2	45
71	p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. <i>Journal of Pathology</i> , 1998 , 184, 265-71	9.4	44
70	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3788-95	2.2	43
69	Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. <i>Oncology</i> , 2004 , 66, 388-94	3.6	43
68	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101965	14.4	39
67	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. <i>PLoS ONE</i> , 2015 , 10, e0126096	3.7	39
66	SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016). <i>Clinical and Translational Oncology</i> , 2016 , 18, 1229-1236	3.6	39
65	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020 , 11, 385	17.4	36
64	Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors. <i>Medical Oncology</i> , 2014 , 31, 783	3.7	36

63	Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 89, 62-72	7	34
62	Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. <i>Breast</i> , 2014 , 23, 710-20	3.6	31
61	Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. <i>British Journal of Cancer</i> , 2009 , 100, 442-9	8.7	30
60	Physical activity and breast cancer risk by pathological subtype. <i>Gynecologic Oncology</i> , 2017 , 144, 577-584	5.9	27
59	Circulating levels of HER-2/neu oncoprotein in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012 , 50, 5-21	5.9	24
58	Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. <i>Annals of Oncology</i> , 2011 , 22, 2591-2596	10.3	22
57	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , 2020 , 21, 1455-1464	21.7	20
56	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , 2017 , 8, 73144-73153	3.3	19
55	Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. <i>Cancer Treatment Reviews</i> , 2008 , 34, 701-9	14.4	18
54	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017 , 23, 3035-3044	12.9	17
53	Predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement: evaluation of two scoring systems. <i>Breast Journal</i> , 2010 , 16, 134-40	1.2	17
52	The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study. <i>PLoS ONE</i> , 2016 , 11, e0159672	3.7	17
51	MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells. <i>Oncotarget</i> , 2017 , 8, 83384-83406	3.3	16
50	Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis. <i>Oncologist</i> , 2015 , 20, 111-2	5.7	15
49	Ingested Nitrate and Breast Cancer in the Spanish Multicase-Control Study on Cancer (MCC-Spain). <i>Environmental Health Perspectives</i> , 2016 , 124, 1042-9	8.4	15
48	Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2016 , 116, 1914-1924.e6	3.9	15
47	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. <i>BMC Medicine</i> , 2019 , 17, 8	11.4	15
46	Trastuzumab in small tumours and in elderly women. <i>Cancer Treatment Reviews</i> , 2014 , 40, 41-7	14.4	14

45	Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013 , 13, 381-91	2.2	14
44	Current perspectives of treatment of ductal carcinoma in situ. <i>Cancer Treatment Reviews</i> , 2010 , 36, 507-17	14.4	14
43	Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. <i>Cancer Treatment Reviews</i> , 2007 , 33, 474-83	14.4	14
42	Changes in metabolic risk, insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors. <i>European Journal of Cancer Care</i> , 2018 , 27, e12861	2.4	13
41	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. <i>Scientific Reports</i> , 2019 , 9, 3904	4.9	12
40	Quality of life during treatment in young women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 123 Suppl 1, 75-7	4.4	12
39	Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study. <i>Environment International</i> , 2019 , 122, 389-399	12.9	12
38	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , 2017 , 22, 1301-1308	5.7	10
37	Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. <i>Annals of Oncology</i> , 2009 , 20, 454-9	10.3	10
36	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 21930-21937	3.3	10
35	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
34	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 115-125	4.4	7
33	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. <i>European Journal of Radiology</i> , 2019 , 117, 132-139	4.7	6
32	Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial. <i>Journal of Human Nutrition and Dietetics</i> , 2019 , 32, 468-479	3.1	5
31	Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. <i>Clinical and Translational Oncology</i> , 2017 , 19, 341-356	3.6	5
30	Infrequent loss of luminal differentiation in ductal breast cancer metastasis. <i>PLoS ONE</i> , 2013 , 8, e78097	3.7	5
29	Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1013-1013	2.2	5
28	Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1023-1023	2.2	4

27	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. <i>Scientific Reports</i> , 2020 , 10, 7741	4.9	4
26	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 303	5.3	3
25	The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials. <i>Clinical Breast Cancer</i> , 2007 , 7, 764-74	3	3
24	Current controversies in the management of early breast cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 375-84	3.6	3
23	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2021 ,	7.9	3
22	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021 , 27, 3116-3125	12.9	3
21	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021 , 69, 103451	8.8	3
20	Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q". <i>Health and Quality of Life Outcomes</i> , 2019 , 17, 143	3	2
19	A phase II clinical trial to analyze olaparib response in patients with BRCA1 and/or BRCA2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS1114-TPS1114	2.2	2
18	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. <i>Nutrients</i> , 2020 , 12,	6.7	2
17	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. <i>Npj Breast Cancer</i> , 2021 , 7, 8	7.8	2
16	Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). <i>European Journal of Cancer Care</i> , 2020 , 29, e13253	2.4	1
15	Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.. <i>European Journal of Cancer</i> , 2022 , 168, 12-24	7.5	1
14	Artificial intelligence supporting cancer patients across Europe-The ASCAPE project.. <i>PLoS ONE</i> , 2022 , 17, e0265127	3.7	1
13	Trajectories of alcohol consumption during life and the risk of developing breast cancer. <i>British Journal of Cancer</i> , 2021 , 125, 1168-1176	8.7	0
12	Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy. <i>Cancer Research</i> , 2022 , 82, P4-10-04-P4-10-04	10.1	0
11	Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials. <i>Cancer Research</i> , 2022 , 82, P4-07-08-P4-07-08	10.1	0
10	Implementing preoperative endocrine therapy in breast cancer. <i>Lancet Oncology</i> , 2020 , 21, 1390-1392	2.7	0

- 9 Scintigraphic evolution of a breast cancer with Tc-99m MIBI scintimammography. *Clinical Nuclear Medicine*, **2000**, 25, 701-3 1.7
- 8 Dietary inflammatory index and breast cancer risk by menopausal status and histological subtype.. *Journal of Clinical Oncology*, **2018**, 36, 1521-1521 2.2
- 7 Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. *Journal of Clinical Oncology*, **2014**, 32, 11107-11107 2.2
- 6 Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.. *Journal of Clinical Oncology*, **2014**, 32, 1602-1602 2.2
- 5 Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. *Journal of Clinical Oncology*, **2016**, 34, 3033-3033 2.2
- 4 Time to definitive deterioration in patients with metastatic breast cancer subjected to second-line monochemotherapy.. *Journal of Clinical Oncology*, **2016**, 34, e12504-e12504 2.2
- 3 Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).. *Journal of Clinical Oncology*, **2021**, 39, 3060-3060 2.2
- 2 CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study.. *Journal of Clinical Oncology*, **2021**, 39, 1014-1014 2.2
- 1 Abstract P4-11-28: Collecting quality of life information in a cohort of breast cancer survivors- Integrating electronic data collection into clinical practice. *Cancer Research*, **2022**, 82, P4-11-28-P4-11-28^{10.1}